Navigation Links
Micromet Added to NASDAQ Biotechnology Index
Date:11/26/2008

se forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on March 14, 2008, as well as other filings by the company
'/>"/>
SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Baylor Research Institute (BRI) at Dallas ... in Phoenix, AZ , today announce an ... for patients with a broad range of cancers. Aligning the ... trials and access to technology to drive the development of ... across Baylor Scott & White Health,s 49 hospitals ...
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. ... that is striving to become a leader in the ... recently announced that the final CVac data from the ... a clear trend for a clinically meaningful improvement in ... second remission patients. In the group of ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Patent Offering, ... method for diagnostic or therapeutic imaging within a body ... uses an endoscope having a low cost, single-use disposable ... filing date was October 18, 2013 and the patent ... technology enables the physician to customize the lighting and ...
(Date:5/21/2015)... 21, 2015 Veolia’s environmental monitoring ... North American distribution agreement with VWR to distribute ... With more than 160 years of experience, VWR, ... for laboratory and production facilities, has cultivated a ... differentiated services to enable science. Endetec’s TECTA™ ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Correction Continues after Big Move - BrokerBank Securities, Inc. 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... Society of Forensic Toxicologists (SOFT) recognizes the recent ... Strengthening Forensic Science in the United States: A ... within the forensic sciences where improvements may be ... education, training, accreditation and certification in forensic science. ...
... superior to synthetic HRT with greater cardiovascular benefits ... 23 The most comprehensive analysis to date, ... peer-reviewed publication for practicing clinicians, showed that bioidentical ... are more efficacious than their synthetic counterparts. Conducted ...
... BOZEN, Italy, February 23 Health Robotics ... a definitive agreement whereby Can-Med,has acquired the ... in Armenia, Georgia, Kazakhstan, Uzbekistan, Azerbaijan,Iran, Mongolia, ... first and only automated, point-of-care-distributed, and fail-safe,robotic ...
Cached Biology Technology:The Society of Forensic Toxicologists Comments on the National Academy of Sciences' Report on 'Strengthening Forensic Science in the United States' 2New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy 2New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy 3Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 3
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... 2010) The Association for Molecular Pathology (AMP) invites ... Annual Meeting and Exhibits and learn about the latest ... four-day event will feature more than 100 corporate exhibits, ... sessions. The keynote speaker is the distinguished recipient of ...
... Chemicals pervade our lives. While the benefits to society ... enabling safer, more efficient and more convenient consumer products ... side. Today, a growing awareness of the risks posed ... stimulated intensive investigations into their lifecycle and the unintended ...
... women who undergo in vitro fertilization (IVF) procedures suffer from ... therapy involved in IVF procedures is primarily responsible for this. ... this is true, other factors are even more influential. ... University,s Sackler Faculty of Medicine and the Sourasky Medical Center ...
Cached Biology News:New book examines health and environmental impacts of common (and not-so-common) chemicals 2New book examines health and environmental impacts of common (and not-so-common) chemicals 3Overcoming the IVF baby blues 2Overcoming the IVF baby blues 3
... MMP-3, Human, Assay, 96 wells. ELISA.Specific ... and complexed MMP-3. No cross-reactivity with MMP-1, ... ng/ml.Suitable for use with cell culture supernatant, ... at -15 to -30 C. Category: ...
... Steady gravity-fed delivery of buffer ... animal perfusion. Rat version. In Vivo ... results--Steady gravity-fed delivery of buffer and ... Easy to setup, use and clean--Complete ...
... 8 micro-bore tubes to 1 outflow ... tips, Rapid (several millisecond) solution change ... prevention , Solid construction 360, 250 ... For mounting on any micromanipulator Available ...
... The steadylite plus assay ... High assay sensitivity, Designed for ... Suitable for higher density microplates ... plates, Odor free, Convenient storage ...
Biology Products: